HCPCS
J9380
1 unit = 0.5 mg
Phase 1
Identify what you're billing
Get the unit basis, step-up schedule, and REMS state right before anything else.
Unit basis — the 0.5 mg trap CMS HCPCS verified May 2026
J9380 is one of a small group of HCPCS codes where 1 unit equals 0.5 mg. Billing it as 1 mg per unit underpays the claim by 50%.
Most J-codes for biologics use a 1 mg per unit basis (e.g., J9299 nivolumab, J9145 daratumumab, J9355 trastuzumab). Tecvayli does not. The official HCPCS descriptor is "Injection, teclistamab-cqyv, 0.5 mg" — meaning every 0.5 mg administered is one billable unit.
Multiply mg by 2 to get units. A 1.5 mg/kg dose for an 80 kg patient is
120 mg administered = 240 units, not 120 units. A step-up Day 1 dose of
0.06 mg/kg for the same patient is 4.8 mg = 9.6 units (round to 10), not 4.8 units.
| Patient weight | Step-up Day 1 (0.06 mg/kg) | Step-up Day 4 (0.3 mg/kg) | Treatment dose (1.5 mg/kg) |
|---|---|---|---|
| 60 kg | 3.6 mg = 7 units | 18 mg = 36 units | 90 mg = 180 units |
| 70 kg | 4.2 mg = 8 units (round) | 21 mg = 42 units | 105 mg = 210 units |
| 80 kg | 4.8 mg = 10 units (round) | 24 mg = 48 units | 120 mg = 240 units |
| 90 kg | 5.4 mg = 11 units (round) | 27 mg = 54 units | 135 mg = 270 units |
| 100 kg | 6 mg = 12 units | 30 mg = 60 units | 150 mg = 300 units |
Round up to whole units. Per CMS billing guidance, partial units are not accepted.
Round up the calculated unit count to the nearest whole number when the dose does not divide evenly
into 0.5 mg increments.
Step-up dosing schedule FDA label verified May 2026
Mandatory step-up dosing in inpatient (or 23-hour observation) setting before any maintenance schedule.
Day 1 · Step-up 1
0.06 mg/kg
Subcutaneous. Premed required (dex + Benadryl + APAP) 1-3 hr prior.
48-hr observation
Day 4 · Step-up 2
0.3 mg/kg
2-7 days after Step-up 1. Premed required.
48-hr observation
Day 7 · Treatment 1
1.5 mg/kg
2-7 days after Step-up 2. First full treatment dose. Premed required.
48-hr observation
Day 14+ · Maintenance
1.5 mg/kg q1w
Weekly outpatient. q2w after ≥6 mo response. No premed required.
Outpatient
48-hour observation required after step-up doses 1, 2, AND first full treatment dose
per FDA label. This is typically delivered in the inpatient setting or as 23-hour observation hospital
outpatient. CRS most commonly occurs within 24-48 hours of step-up dosing. Tocilizumab (Actemra)
must be on hand for IV administration if Grade 2+ CRS develops.
Q2 weekly dosing transition (label option)
After at least 6 months of weekly Tecvayli with sustained response (≥VGPR for ≥6 months), the FDA label permits transition from 1.5 mg/kg SC weekly to 1.5 mg/kg SC every 2 weeks (q2wk). This roughly halves total annual drug exposure and cost.
Payer policy lag for q2wk dosing. UHC, Aetna, and Cigna policies are still being
updated to reflect the q2wk option. Verify per-payer coverage before transitioning, as some PA
renewals still expect weekly billing intervals. Submit response documentation (M-protein, FLC ratio,
marrow plasma cell %) when requesting q2wk transition.
Re-initiation after dose delay
Per the FDA label, if a maintenance dose is delayed beyond a defined interval (e.g., >7 days from last weekly dose, >14 days from last q2wk dose), the step-up sequence may need to be re-initiated. Verify the current label thresholds before re-initiating — this is a billing event and a clinical safety event. Re-initiation triggers another inpatient admission for step-up.
Dosing & unit math worked examples FDA label verified May 2026
From Tecvayli HCP page and the FDA prescribing information.
Worked example — first 4 doses for an 80 kg patient (Cycle 1, weekly schedule)
# Patient: 80 kg adult, 5L+ R/R MM (post-Darzalex, lenalidomide, bortezomib, carfilzomib)
# Step-up Day 1: 0.06 mg/kg SC = 4.8 mg
Drug units billed: 10 (J9380, round 9.6 up)
Modifier: JZ (single-dose vial, no waste from 30 mg vial)
Admin: 96401 (chemo SC)
Site: Inpatient (DRG 825) — 48-hr observation
# Step-up Day 4: 0.3 mg/kg SC = 24 mg
Drug units billed: 48 (J9380)
Modifier: JZ + JW for 6 mg waste (30 mg vial - 24 mg admin)
Site: Inpatient continued, 48-hr observation
# Day 7: First treatment dose 1.5 mg/kg = 120 mg
Drug units billed: 240 (J9380, uses 153 mg vial)
Modifier: JZ + JW for 33 mg waste (153 mg vial - 120 mg admin)
Site: Inpatient continued, 48-hr observation
# Day 14+ Weekly maintenance: 1.5 mg/kg SC = 120 mg
Drug units billed per dose: 240
Site: Outpatient infusion center / oncology office (POS 11/49)
Annual (52 weekly doses): 12,480 units
Annual cost (Q2 2026 ASP+6%): ~$430,572 before sequestration
# Step-up Day 1: 0.06 mg/kg SC = 4.8 mg
Drug units billed: 10 (J9380, round 9.6 up)
Modifier: JZ (single-dose vial, no waste from 30 mg vial)
Admin: 96401 (chemo SC)
Site: Inpatient (DRG 825) — 48-hr observation
# Step-up Day 4: 0.3 mg/kg SC = 24 mg
Drug units billed: 48 (J9380)
Modifier: JZ + JW for 6 mg waste (30 mg vial - 24 mg admin)
Site: Inpatient continued, 48-hr observation
# Day 7: First treatment dose 1.5 mg/kg = 120 mg
Drug units billed: 240 (J9380, uses 153 mg vial)
Modifier: JZ + JW for 33 mg waste (153 mg vial - 120 mg admin)
Site: Inpatient continued, 48-hr observation
# Day 14+ Weekly maintenance: 1.5 mg/kg SC = 120 mg
Drug units billed per dose: 240
Site: Outpatient infusion center / oncology office (POS 11/49)
Annual (52 weekly doses): 12,480 units
Annual cost (Q2 2026 ASP+6%): ~$430,572 before sequestration
Vial waste planning
- 30 mg / 3 mL vial: use for step-up Day 1 (typically 3-7 mg dose — large waste, document JW) and step-up Day 4 (typically 18-30 mg — smaller waste, document JW).
- 153 mg / 1.7 mL vial: use for full treatment doses (1.5 mg/kg, 90-150 mg range — partial-vial waste, document JW).
- Combine vials only when label-permitted to minimize discard. Always bill JW for the discarded portion on a separate claim line.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Package | Use |
|---|---|---|
57894-107-01 / 57894-0107-01 |
30 mg / 3 mL (10 mg/mL) single-dose vial — 1 vial per carton | Step-up Day 1 (0.06 mg/kg) and Step-up Day 4 (0.3 mg/kg) doses |
57894-108-01 / 57894-0108-01 |
153 mg / 1.7 mL (90 mg/mL) single-dose vial — 1 vial per carton | First treatment dose (Day 7) and ongoing 1.5 mg/kg maintenance doses |
Use carton-level NDC, not vial-level. Payers expect the carton NDC on the claim form
with the N4 qualifier in box 24A shaded area. Submit the unit of measure (ML) and total volume
administered.
Two concentrations matter clinically. The 30 mg/3 mL and 153 mg/1.7 mL vials are
NOT interchangeable on a mL-for-mL basis — they have different mg/mL strengths. Always
select vial by mg dose, not by volume.
Tecvayli REMS — required REMS verified May 2026
Tecvayli is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program due to boxed warnings for CRS and ICANS.
The Tecvayli REMS is a closed distribution program. All four parties must be certified or enrolled before any dose can be dispensed or administered:
- Prescribers: complete training program and enroll in the Tecvayli REMS
- Healthcare facilities: certify that on-site personnel can recognize and manage CRS and ICANS, and that tocilizumab (Actemra) is immediately available for IV administration
- Pharmacies (specialty/inpatient): certify and verify prescriber and facility enrollment before dispensing
- Patients: enroll, receive counseling on CRS/ICANS warning signs, carry a wallet card at all times during therapy and for the period defined by the label after the last dose
How to enroll
- Web: tecvaylirems.com
- Phone: Tecvayli REMS Coordinating Center (consult tecvaylirems.com for current number)
- Documentation: retain REMS enrollment confirmation in patient chart and on PA submissions
Common error: dispensing or administering Tecvayli without verifying patient and
facility REMS enrollment. Triggers FDA reporting, claim denial, payer audit, and recoupment of paid
claims. Verify all four certifications BEFORE every first dose and document re-verification at
defined intervals per the REMS program.
Phase 2
Code the claim
Subcutaneous oncology biologic uses chemo-admin SC code, not therapeutic SC.
Administration codes CPT verified May 2026
Tecvayli is a complex monoclonal antibody bispecific given subcutaneously and bills under chemotherapy administration.
| Code | Description | When to use |
|---|---|---|
96401 |
Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic | Primary code for Tecvayli SC. Used for the SC oncology biologic injection. |
96372 |
Therapeutic, prophylactic, or diagnostic injection (specify substance/drug); SC or IM | Some payers accept this for monoclonal SC injections. Lower reimbursement than 96401. Use only if your payer rejects 96401. |
96365 / 96413 |
IV infusion codes | NOT appropriate. Tecvayli is SC only. |
Why chemo-SC for an immunotherapy biologic: CPT 96401 is the correct admin code for
complex monoclonal antibody SC administration regardless of mechanism of action. Bispecifics like
Tecvayli, Talvey (talquetamab), and Elrexfio (elranatamab) all bill under 96401 for the SC injection.
Inpatient site billing: When step-up doses are administered during an inpatient
admission, the drug AND the admin are typically bundled into the DRG (DRG 825 multiple myeloma w/ MCC
is common). The hospital does not bill J9380 + 96401 separately during the inpatient episode —
coverage is via the DRG. J9380 + 96401 line-item billing applies once the patient transitions to
outpatient maintenance.
Modifiers CMS verified May 2026
JZ — required when no waste
Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. For Tecvayli, JZ applies when the entire vial contents are administered without waste — rare given weight-based dosing rarely matches the 30 mg or 153 mg vial sizes exactly.
JW — report wasted drug (typical case for Tecvayli)
JW reports the discarded portion of a single-dose vial. Because Tecvayli is weight-based and vial sizes are 30 mg and 153 mg, almost every dose generates partial-vial waste. Bill JW with the discarded units on a separate claim line. Example: 1.5 mg/kg SC dose for an 80 kg patient = 120 mg administered (240 units, JZ if no waste OR JW for any remaining); 153 mg vial used → 33 mg discarded = 66 units of JW waste.
One of JZ or JW must be on every J9380 claim. CMS audits often catch missing JW
on weight-based oncology biologics. Wasted drug is reimbursable but must be reported.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the SC administration. Routine pre-injection clinical assessment is bundled.
340B modifiers (JG, TB)
For 340B-acquired Tecvayli, follow your MAC's current 340B modifier policy. Janssen's billing guide does not provide 340B-specific instructions.
ICD-10-CM — multiple myeloma FY2026 verified May 2026
Tecvayli is approved only for relapsed/refractory MM after ≥4 prior lines. Almost all encounters use the "in relapse" subcategory.
| Code | Description | Use for Tecvayli |
|---|---|---|
C90.00 | Multiple myeloma, not having achieved remission | Newly diagnosed at time of Tecvayli initiation (rare for 4L+ population) |
C90.01 | Multiple myeloma in remission | Patient in CR/VGPR but continuing therapy |
C90.02 | Multiple myeloma in relapse | Most common for Tecvayli — relapsed/refractory population by definition |
Document prior lines explicitly in the PA. ICD-10 alone is not sufficient. The PA
narrative must list all prior MM regimens with class (PI, IMiD, anti-CD38) and outcome (progression
vs intolerance). UHC, Aetna, and Cigna enforce the ≥4 prior lines requirement strictly — a
single missing line triggers immediate denial.
Required prior therapy classes
- Proteasome inhibitor (PI): bortezomib (Velcade), carfilzomib (Kyprolis), ixazomib (Ninlaro)
- Immunomodulatory agent (IMiD): lenalidomide (Revlimid), pomalidomide (Pomalyst), thalidomide (Thalomid)
- Anti-CD38 monoclonal antibody: daratumumab (Darzalex / Darzalex Faspro) or isatuximab (Sarclisa)
Site of care & place of service Verified May 2026
Step-up phase = inpatient. Maintenance phase = outpatient. The transition is the billing inflection point.
| Phase | Setting | POS | Claim form | Billing |
|---|---|---|---|---|
| Step-up Day 1 | Inpatient hospital | 21 | UB-04 / 837I | DRG 825 (MM w/ MCC) bundled |
| Step-up Day 4 | Inpatient hospital (continued) | 21 | UB-04 / 837I | DRG bundled |
| Treatment Day 7 | Inpatient hospital (continued) | 21 | UB-04 / 837I | DRG bundled |
| Treatment Day 7 (alternative) | Hospital outpatient (23-hr observation) | 22 | UB-04 / 837I | OPPS APC + J9380 + 96401 |
| Maintenance (Day 14+) | Hospital outpatient infusion | 22 | UB-04 / 837I | OPPS APC + J9380 + 96401 |
| Maintenance (preferred) | Oncology office | 11 | CMS-1500 / 837P | J9380 + 96401 line-item |
| Maintenance (preferred) | Ambulatory infusion center (AIC) | 49 | CMS-1500 / 837P | J9380 + 96401 line-item |
| Maintenance | Oncology ASC | 24 | CMS-1500 / 837P | Acceptable |
Step-up doses MUST be administered in a setting equipped for CRS/ICANS management.
Most institutions use the inpatient ward (with bispecific protocols and tocilizumab on hand) or
23-hour observation hospital outpatient with intensivist coverage. Outpatient office and AIC
settings are NOT appropriate for step-up doses.
Maintenance steerage to outpatient: UnitedHealthcare and Aetna both steer Tecvayli
maintenance out of HOPD once the patient has cleared step-up and the first 1-2 cycles. Move to
oncology office (POS 11) or AIC (POS 49) for ongoing weekly or q2w dosing once your facility's
clinical protocol allows.
Claim form field mapping Janssen 2026
Maintenance phase outpatient billing — CMS-1500 / 837P. Step-up phase inpatient bills via UB-04 under DRG.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + carton NDC + ML + total volume (e.g. 1.7 mL for 153 mg vial use) |
| HCPCS J9380 + JZ (or JW for waste) | 24D (drug line) | Multiply mg by 2 to get units — 0.5 mg unit basis |
| Drug units | 24G | e.g. 240 units for 120 mg dose |
| JW waste claim line (separate) | 24D + 24G | Discarded units, e.g. 66 units for 33 mg waste from 153 mg vial |
| CPT 96401 (admin line) | 24D (admin line) | Chemo SC, non-hormonal |
| ICD-10 | 21 | C90.02 (in relapse) most common |
| PA number | 23 | Required by all major payers |
| REMS enrollment confirmation | Chart + PA narrative | Document Tecvayli REMS enrollment for prescriber, site, and patient |
Phase 3
Get paid
REMS confirmation + 4L+ documentation are the two PA must-haves. Skip either and the claim dies.
Payer policy snapshot Reviewed May 2026
All major payers require PA, ≥4L documentation, and REMS enrollment confirmation.
| Payer | PA? | Key requirements | Site-of-care UM |
|---|---|---|---|
| UnitedHealthcare Oncology Med Coverage Policy |
Yes | ≥4 prior lines documented (PI + IMiD + anti-CD38), REMS enrollment confirmation, Tecvayli REMS site certification | Steers maintenance out of HOPD after step-up clearance via Optum-managed program |
| Aetna CPB + Medical Drug policies |
Yes | ≥4 prior lines, REMS enrollment, ECOG 0-2, age ≥18, MM diagnosis confirmed | Yes (separate Site-of-Care policy; bispecific maintenance steered to office/AIC) |
| Cigna Coverage Policy |
Yes | Aligned with FDA label and NCCN MM Guidelines (4L+ bispecific recommendation), REMS confirmation | Plan-specific; most have bispecific site-of-care steering |
| Medicare LCDs All MACs |
No (PA), but documentation required | Cover for FDA label indication with appropriate ICD-10 (C90.02) and prior therapy documentation | N/A (Medicare FFS) |
NCCN Guidelines
NCCN Multiple Myeloma Guidelines (current version) include teclistamab as a recommended option in 4L+ relapsed/refractory disease alongside other BCMA-directed therapies (cilta-cel, ide-cel, elranatamab) and the GPRC5D bispecific talquetamab. NCCN compendium support strengthens off-label coverage arguments where applicable.
Step therapy
Tecvayli is itself the late-line therapy. Prior therapy steps are baked into the FDA label requirement (PI + IMiD + anti-CD38). Some payers may require trial of a CAR-T product (cilta-cel/Carvykti or ide-cel/Abecma) before bispecific therapy in eligible patients; this is plan-specific and increasingly being relaxed as bispecifics mature.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J9380
Effective April 1 – June 30, 2026 · Based on Q4 2025 ASP submissions
ASP + 6%
$34.501
per 0.5 mg unit
1.5 mg/kg @ 80 kg dose
$8,280.24
120 mg = 240 units
Annual weekly maint. @ 80 kg
~$430,572
52 weekly doses
Per-mg comparison (for sanity-check): $34.501 per 0.5 mg = $69.002 per mg.
If your billing software shows a per-mg cost in this range, the 0.5 mg unit basis is being applied correctly.
Inpatient step-up phase is bundled: The first three doses (step-up Day 1, Day 4, treatment
Day 7) are typically administered during a single inpatient admission and reimbursed under the DRG (commonly
DRG 825 multiple myeloma w/ MCC). J9380 line-item billing applies to outpatient maintenance only.
Coverage
No NCD specific to teclistamab. Coverage falls under MAC LCDs for biologics + the generic drug-coverage framework. All MACs cover J9380 for the FDA-approved indication with appropriate ICD-10, prior therapy documentation, and REMS enrollment confirmation.
Code history
- J9380 — permanent code, effective July 1, 2023 (initial FDA approval was October 25, 2022; pre-permanent-code period used unclassified J3490 / J9999)
Patient assistance — Janssen CarePath Janssen verified May 2026
- Janssen CarePath: 1-877-CarePath (1-877-227-3728) / janssencarepath.com — benefits investigation, prior authorization assistance, appeal support
- Tecvayli Savings Program: commercially-insured patients may pay as little as $0 for the first dose and have annual support up to defined caps (~$25,000/year typical). Excludes Medicare, Medicaid, Tricare, VA/IHS
- Johnson & Johnson Patient Assistance Foundation: free product for uninsured patients meeting income criteria, and a separate hardship pathway for Medicare patients facing affordability burden
- Foundations (Medicare): for Medicare patients, refer to PAN, HealthWell, CancerCare — verify open multiple myeloma funds quarterly
- Web: janssencarepath.com/patient/tecvayli
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — J9380 pre-loaded.
Phase 4
Manage toxicity and fix problems
CRS/ICANS protocol, denial fixes, and FAQ.
CRS / ICANS management FDA boxed warning verified May 2026
BOXED WARNING — Cytokine Release Syndrome (CRS): life-threatening or fatal CRS
can occur. CRS occurred in approximately 72% of patients in the MajesTEC-1 trial,
most commonly during the step-up phase. Most events were Grade 1-2; Grade 3+ in ~0.6%. Tocilizumab
(Actemra J3262) must be immediately available for IV administration.
BOXED WARNING — Neurologic Toxicity including ICANS: life-threatening or fatal
neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),
occurred in approximately 15% of patients (Grade 3+ ~0.6%). Monitor for
encephalopathy, headache, motor weakness, seizures. Withhold or discontinue per label grading.
Tocilizumab (Actemra) on hand — required
Per the Tecvayli REMS, the administering facility must have tocilizumab (Actemra, HCPCS J3262) immediately available for IV administration to manage CRS Grade 2+. Verify supply before each step-up dose. Tocilizumab dosing for CRS: 8 mg/kg IV (max 800 mg) per the Actemra label for CRS management.
Pre-medication for step-up & first treatment dose
- Dexamethasone: 16 mg IV or oral, 1-3 hours before each of the first three doses
- Diphenhydramine: 50 mg IV or oral, 1-3 hours before each of the first three doses
- Acetaminophen: 650-1000 mg oral, 1-3 hours before each of the first three doses
- Not required for ongoing maintenance doses after Cycle 1 once tolerability is established
Monitoring requirements
- 48-hour observation after each of the first three doses (step-up 1, step-up 2, first treatment)
- Daily symptom assessment (fever, hypoxia, hypotension, neurologic status) during observation
- Patient counseling on warning signs; wallet card describes when to seek emergency care
- Avoid driving and operating hazardous machinery for the period defined in the label after each dose
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Wrong unit basis (50% underpayment) | Billed mg as units instead of multiplying by 2 | Resubmit corrected claim. 1.5 mg/kg @ 80 kg = 120 mg = 240 units (not 120). |
| REMS not documented | PA submitted without Tecvayli REMS enrollment confirmation | Submit REMS enrollment letter + facility certification. Add to chart and PA narrative for all future claims. |
| Prior lines not documented | PA narrative missing one of PI / IMiD / anti-CD38 | Submit complete prior therapy log with regimen, dates, and outcome. All three classes must be present. |
| JW missing on weight-based dose | Wasted drug not reported | Add JW line for discarded units. JZ on administered units (or omit JZ if any waste); JW on the wasted units. |
| Wrong admin code (96372 vs 96401) | Therapeutic SC code instead of chemo SC | Resubmit with 96401 if payer accepts. 96401 is the correct chemo-admin code for SC oncology biologics. |
| Site of care (HOPD maintenance) | HOPD billing for ongoing maintenance after step-up clearance | Move to office (POS 11) or AIC (POS 49). Submit medical necessity letter if HOPD required for medical reasons. |
| q2wk dosing not authorized | Payer policy not yet updated for q2wk transition | Submit response documentation (M-protein, FLC ratio, marrow plasma %); request policy review citing FDA label q2wk option. |
| Dose delay re-initiation not coordinated | Maintenance dose missed beyond label threshold; full step-up re-required | Re-coordinate inpatient admission for re-initiated step-up; submit clinical narrative for the re-initiation event. |
Frequently asked questions
What is the HCPCS code for Tecvayli?
Tecvayli (teclistamab-cqyv) is billed under HCPCS J9380 — "Injection,
teclistamab-cqyv, 0.5 mg." The unit basis is unusual: 1 unit = 0.5 mg, NOT 1 mg.
This is the most common billing error for J9380. A 1.5 mg/kg dose for an 80 kg patient (120 mg)
bills as 240 units, not 120 units. J9380 was effective July 1, 2023.
How many units do I bill for a Tecvayli dose?
Multiply mg by 2 to get units. Step-up Day 1 (0.06 mg/kg) for an 80 kg patient = 4.8 mg = 9.6 → round to 10 units. Step-up Day 4 (0.3 mg/kg) = 24 mg = 48 units. First treatment dose Day 7 (1.5 mg/kg) = 120 mg = 240 units. Maintenance (1.5 mg/kg weekly or q2wk after ≥6 months) = 240 units per dose for an 80 kg patient.
What administration CPT do I use for Tecvayli?
CPT 96401 — "Chemotherapy administration, subcutaneous or intramuscular;
non-hormonal anti-neoplastic." Tecvayli is a complex monoclonal antibody bispecific given
subcutaneously and is classified for billing as chemotherapy administration. Some payers will
accept 96372 (therapeutic SC injection) but 96401 is the more accurate and
higher-reimbursing code for oncology biologics.
Does Tecvayli require REMS enrollment?
Yes. Tecvayli is available only through the Tecvayli REMS program because of the boxed warnings for cytokine release syndrome (CRS) and neurologic toxicity including ICANS. Prescribers, healthcare facilities, pharmacies, AND patients must all be certified or enrolled. Patients receive a wallet card. Document REMS enrollment in the chart and confirm enrollment when submitting prior authorization.
What is the Medicare reimbursement for J9380?
For Q2 2026, the Medicare Part B payment limit for J9380 is $34.501 per 0.5 mg unit (ASP + 6%). A 1.5 mg/kg full treatment dose for an 80 kg patient (120 mg = 240 units) reimburses at approximately $8,280.24. Annualized weekly maintenance cost: approximately $430,572. After ~2% sequestration: roughly $421,800/year actual paid. Step-up doses delivered inpatient are typically bundled into the DRG, not billed line-item under J9380.
Why must Tecvayli step-up dosing be inpatient?
Per FDA label, patients must remain under observation for 48 hours after each of the first three doses (step-up Day 1, step-up Day 4, and the first treatment dose Day 7) due to the risk of life-threatening cytokine release syndrome (CRS, ~72% of patients) and ICANS (~15%). CRS rates drop sharply after the step-up phase. Ongoing weekly or q2wk maintenance after the third dose can typically be administered outpatient at infusion centers, oncology offices, or AICs equipped to monitor for delayed CRS.
What is the 1.5 mg/kg q2wk option for Tecvayli?
After at least 6 months of weekly Tecvayli with a sustained response (≥VGPR for 6 months), the FDA label allows transition from 1.5 mg/kg SC weekly to 1.5 mg/kg SC every 2 weeks (q2wk). This roughly halves drug exposure and total annual cost. Payer policies are still updating to reflect this dosing flexibility — verify per-payer coverage of the q2wk schedule before transitioning.
What are the prior therapy requirements for Tecvayli?
Tecvayli is FDA-approved for adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor (e.g., bortezomib, carfilzomib), an immunomodulatory agent (e.g., lenalidomide, pomalidomide), and an anti-CD38 monoclonal antibody (e.g., daratumumab/Darzalex). Prior auth submissions must document each prior line, the agent class, and treatment failure (progression or intolerance).
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- Tecvayli HCP page (Janssen Biotech)
- DailyMed — TECVAYLI (teclistamab-cqyv) Prescribing Information
- Tecvayli REMS Program
- CMS — Medicare Part B Drug ASP Pricing File
- FDA Approval Announcement — Teclistamab-cqyv (Oct 25, 2022)
- Janssen CarePath — Tecvayli
- NCCN Multiple Myeloma Guidelines
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy
- Aetna Clinical Policy Bulletin — Multiple Myeloma Therapies
- FDA National Drug Code Directory
- CMS Medicare Coverage Database (LCDs)
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, Cigna) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, REMS | Event-driven | Tied to manufacturer document version + FDA label revision date + REMS program updates. |
| Tecvayli REMS program | Event-driven | Verified against tecvaylirems.com on each review cycle. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
manufacturer, REMS program, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft
reference and verify each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. Manufacturer source: Janssen 2026. FDA label: most recent revision (BLA 761291, original approval Oct 25, 2022). 0.5 mg unit basis emphasized as primary biller error trap. Step-up dosing schedule, REMS, and CRS/ICANS management documented. q2wk maintenance option (post-6-month response) noted with payer-policy lag warning.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication and dosing are verified against the current FDA label revision. REMS program details are verified at tecvaylirems.com. We do not paraphrase from billing-software vendor blogs.